VivoSpiro digital inhaler and PM&HM digital therapy control technologies can be used at all stages of asthma.
Short-acting β2-agonists (SABA) are used in nebulizers when the condition worsens or aggravates. Their administration is accompanied by serious side effects (primarily stress on the heart). Accurate dosing can minimize the side effects of SABA.

Inhalant glucocorticosteroids (iGCS) are used at all stages of asthma development as the main control drug. In addition, iGCS are used for severe attacks and resuscitation in medical facilities. Such situations are possible at any stage of the development of the disease. In this case, accurate dosing is critical for effective treatment facilitation.

Lengthening or increased frequency of attacks often requires increasing the dose of iGCS. Using our technologies, the doctor can remotely control the dose of any drug, change it depending on the patient's condition and receive data on the actual dose administered. This is possible not only at those stages where iGCS is used as a monotherapy. In the case of using a combination of iGCS/LABA (long-acting β2-agonists), a third of patients prefer to separately inhale LABA, and then use iGCS (two inhalers). This is more convenient to increase the dose of iGCS, and maintain a constant dose of LABA (as they are extremely cardiotoxic).

Budesonide is the only iGCS drug allowed for pregnant women. Its accurate dosing will minimize side effects and make the treatment as safe as possible for pregnant women.

Target segments for the technologies (according to the GINA 2020 recommendations for bronchial asthma management):
VivoSpiro inhaler compatible drugs, as per laboratory tests:
1. Budesonide (iGCS)
2. Beclometasone (iGCS)
3. Salbutamol (SABA)
4. Fenoterol (SABA)
5. Formoterol (LABA)
6. Tiotropium bromide (m-anticholinergics)
7. Ipratropium bromide (m-anticholinergics)